The in vitro experiments such as the interferon-γ (IFN-γ) release assays and the cell-killing assay using AML samples also confirm the tumor-reactive property of ADGRG1+CD8+ T cells. This evidence concerns the gene ADGRG1 and acute myeloid leukemia.